Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

ceftolozane, tazobactam drug combination 2Meropenem 2Itraconazole 2rasburicase 1pegylated granulocyte colony-stimulating factor 1pegaspargase 1fludarabine phosphate 1fludarabine 1eltrombopag 1drotrecogin alfa activated 1dexamethasone 21-phosphate 1Voriconazole 1Vancomycin 1Uric Acid 1Urate Oxidase 1Tropisetron 1Teicoplanin 1Solutions 1Ribavirin 1Pegloticase 1Oxidoreductases 1Ofloxacin 1Micafungin 1Metronidazole 1Imatinib Mesylate 1Hydromorphone 1Human Papillomavirus Recombinant Vaccine nonavalent 1Dexamethasone 1Dasatinib 1Ciprofloxacin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Hematologic Neoplasms × Pegloticase × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡